MelindaLTelliMD

Oncology • Palo Alto, CA

Breast Cancer

Associate Professor of Medicine - Oncology, Stanford University Medical Center

Join to view full profile

Dr. Telli is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Telli's full profile

Already have an account?

Office
900 Blake Wilbur Dr
Palo Alto, CA 94304
Phone+1 650-498-6004

Fax+1 650-498-7237
Is this information wrong?

Education & Training

Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 2002 - 2005
George Washington University School of Medicine and Health SciencesClass of 2002

Certifications & Licensure

CA State Medical License 2003 - 2025
FL State Medical License 2020 - 2022

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women Start of enrollment: 2000 Oct 01
Completed
Phase 2
Development of Vitamin D as a Therapy for Breast Cancer - Phase 2 Start of enrollment: 2008 Apr 01
Completed
Phase 2
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Vitamin D and Breast Cancer: Does Weight Make a Difference? Start of enrollment: 2011 Nov 01
Terminated
Phase 2
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer Start of enrollment: 2012 Jun 13
Completed
Phase 2
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer Start of enrollment: 2012 Aug 01
Completed
Phase 2
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI Start of enrollment: 2013 May 31
Completed
Phase 2
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Start of enrollment: 2014 Feb 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Tumor-Infiltrating lymphocytes and breast cancer mortality in racially and ethnically diverse participants of the Northern California breast cancer family registry.
Julia D Ransohoff, Iain Miller, Jocelyn Koo, Vishal Joshi, Allison W Kurian, Kimberly H Allison, Esther M John, Melinda L Telli> ;JNCI Cancer Spectrum. 2024 Mar 28
Generation and characterization of induced pluripotent stem cells from breast cancer patients carrying ATM mutations.
Mao Zhang, Ravichandra Venkateshappa, Audrey Li, Michael B Fowler, Melinda L Telli, Joseph C Wu> ;Stem Cell Research. 2023 Dec 1
1 citations
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study.
Nicholas C Turner, A Douglas Laird, Melinda L Telli, Hope S Rugo, Audrey Mailliez, Johannes Ettl, Eva-Maria Grischke, Lida A Mina, Judith Balmaña, Peter A Fasching, Sa...> ;NPJ Breast Cancer. 2023 Oct 6
Generation of two induced pluripotent stem cell lines from breast cancer patients carrying BRCA2 variants.
Mao Zhang, Wenqiang Liu, Audrey Li, Min H Htet, Rebecca Yu, Melinda L Telli, Joseph C Wu> ;Stem Cell Research. 2023 Oct 1
1 citations
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
Lauren Lenz, Chris Neff, Cara Solimeno, Elizabeth S Cogan, Vandana G Abramson, Judy C Boughey, Carla Falkson, Matthew P Goetz, James M Ford, William J Gradishar, Rache...> ;Breast Cancer Research and Treatment. 2023 Nov 1
2 citations
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study.
Jennifer K Litton, J Thaddeus Beck, Jason M Jones, Jay Andersen, Joanne L Blum, Lida A Mina, Raymond Brig, Michael Danso, Yuan Yuan, Antonello Abbattista, Kay Noonan, ...> ;The Oncologist. 2023 Oct 3
7 citations
Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer.
Julia D Ransohoff, Victor Ritter, Natasha Purington, Karen Andrade, Summer Han, Mina Liu, Su-Ying Liang, Esther M John, Scarlett L Gomez, Melinda L Telli, Lidia Schapi...> ;Nature Communications. 2023 Apr 12
20 citations
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
Timothy A Yap, Aditya Bardia, Michael Dvorkin, Matthew D Galsky, J Thaddeus Beck, David R Wise, Oleg Karyakin, Gábor Rubovszky, Nikolay Kislov, Kristoffer Rohrberg, An...> ;JAMA Oncology. 2023 Jan 1
18 citations
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Ag...
Alison M Schram, Nicoletta Colombo, Edward Arrowsmith, Vivek Narayan, Kan Yonemori, Giovanni Scambia, Amelia Zelnak, Todd M Bauer, Ning Jin, Susanna V Ulahannan, Marco...> ;JAMA Oncology. 2023 Jan 1
3 citations
Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
Tanya Gupta, Shaveta Vinayak, Melinda Telli> ;Breast Cancer Research and Treatment. 2023 Jan 1
38 citations
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.
Joshua J Gruber, Anosheh Afghahi, Kirsten Timms, Alyssa DeWees, Wyatt Gross, Vasily N Aushev, Hsin-Ta Wu, Mustafa Balcioglu, Himanshu Sethi, Danika Scott, Jessica Fora...> ;Nature Cancer. 2022 Oct 1
28 citations
Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update.
N Lynn Henry, Mark R Somerfield, Zoneddy Dayao, Anthony Elias, Kevin Kalinsky, Lisa M McShane, Beverly Moy, Ben Ho Park, Kelly M Shanahan, Priyanka Sharma, Rebecca Sha...> ;Journal of Clinical Oncology. 2022 Sep 20
285 citations
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Elias, A., Savur Moran, M. S., William J Gradishar, Meena S Moran, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H Allison, Bethany Anderson, Harold J Burstein, H...> ;Journal of the National Comprehensive Cancer Network. 2022 Jun 1
19 citations
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial.
Funda Meric-Bernstam, Nizar M Tannir, Othon Iliopoulos, Richard J Lee, Melinda L Telli, Alice C Fan, Angela DeMichele, Naomi B Haas, Manish R Patel, James J Harding, M...> ;Clinical Cancer Research. 2022 Apr 14
16 citations
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer.
Melinda L Telli, Sara M Tolaney, Geoffrey I Shapiro, Mark Middleton, Simon R Lord, Hendrik Tobias Arkenau, Andrew Tutt, Vandana Abramson, Emma Dean, Tufia C Haddad, Ro...> ;NPJ Breast Cancer. 2022 Apr 7
6 citations
Adjuvant Abemaciclib Plus Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A.
Rachel A Freedman, Stephanie L Graff, Mark R Somerfield, Melinda L Telli, Antonio C Wolff, Sharon H Giordano> ;JCO Oncology Practice. 2022 Jul 1
10 citations
Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
Julia Dixon-Douglas, Sibylle Loibl, Carsten Denkert, Melinda Telli, Sherene Loi> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2022 Apr 1
19 citations
A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors.
James J. Harding, Melinda L. Telli, Pamela N. Munster, Martin H. Voss, Jeffrey R. Infante, Angela DeMichele, Mark Dunphy, Mai H. Le, Christopher J. Molineaux, Keith W....> ;Clinical Cancer Research. 2021 Jul 20
25 citations
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
Linda T. Vahdat, Peter Schmid, Andres Forero-Torres, Kimberly L. Blackwell, Melinda L. Telli, Michelle E. Melisko, Volker Möbus, Javier Cortes, Alberto J. Montero, Cyn...> ;NPJ Breast Cancer. 2021 May 20
26 citations
Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy.
Melinda L. Telli, Hiroshi Nagata, Irene Wapnir, Chaitanya R. Acharya, Kaitlin Zablotsky, Bernard A. Fox, Carlo Bifulco, Shawn M. Jensen, Carmen Ballesteros-Merino, Mai...> ;Clinical Cancer Research. 2021 May 1
150 citations
NCCN Guidelines® Insights: Breast Cancer, Version 4.2021.
William J Gradishar, Meena S Moran, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H Allison, Sarah L Blair, Harold J Burstein, Chau Dang, Anthony D Elias, Sharon ...> ;Journal of the National Comprehensive Cancer Network. 2021 May 1
45 citations
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update
Neelima Denduluri, Mark R. Somerfield, Mariana Chavez-MacGregor, Amy Comander, Zoneddy Dayao, Andrea Eisen, Rachel A. Freedman, Ragisha Gopalakrishnan, Stephanie L. Gr...> ;Journal of Clinical Oncology. 2021 Feb 20
477 citations
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stag...
Elizabeth A. Mittendorf, Hong Zhang, Carlos H. Barrios, Shigehira Saji, Kyung Hae Jung, Roberto Hegg, Andreas Koehler, Joohyuk Sohn, Hiroji Iwata, Melinda L. Telli, Cr...> ;Lancet. 2020 Oct 10
BROCADE3: a challenge to the treatment paradigm in BRCA breast cancer?
Melinda L. Telli> ;The Lancet. Oncology. 2020 Aug 27
18 citations
Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Poole...
Melinda L. Telli, Charles Chu, Sunil Badve, Shaveta Vinayak, Daniel P. Silver, Steven J. Isakoff, Virginia G. Kaklamani, William J. Gradishar, Vered Stearns, Roisin M....> ;Clinical Cancer Research. 2020 Jun 1
Join now to see all

Lectures

Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in ear...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

NCCN: Updated Guidelines Reflect Advances, ‘Immunotherapy Era’ for Breast CancerApril 15th, 2019
Technique Could Help Identify Patients Who Would Suffer Chemo-Induced Heart DamageApril 18th, 2016
SABCS® Daily Highlights for Friday, December 8December 20th, 2023
Join now to see all